Synthesis and evaluation of a class of 1,4,7-triazacyclononane derivatives as iron depletion antitumor agents
作者:Sheng Wang、Yongkang Gai、Shasha Zhang、Lei Ke、Xiang Ma、Guangya Xiang
DOI:10.1016/j.bmcl.2017.11.048
日期:2018.1
Iron depletion has been confirmed as an efficient strategy for cancer treatment. In the current study, a series of 1,4,7-triazacyclononane derivatives HE-NO2A, HP-NO2A and NE2P2A, as well as the bifunctional chelators p-NO2-PhPr-NE3TA and p-NH2-PhPr-NE3TA were synthesized and evaluated as iron-depleting agents for the potential anti-cancer therapy against human hepatocellular carcinoma. The cytotoxicity
铁消耗已被确认为治疗癌症的有效策略。在当前的研究中,一系列1,4,7-三氮杂环壬烷衍生物HE-NO2A,HP-NO2A和NE2P2A,以及双功能螯合剂p -NO 2 -PhPr-NE3TA和p -NH 2合成了-PhPr-NE3TA,并将其作为铁消耗剂进行评估,以用于潜在的抗人肝细胞癌抗癌治疗。使用肝细胞癌细胞测量了这些螯合剂的细胞毒性,并与临床上可用的铁耗竭剂DFO和通用金属螯合剂DTPA进行了比较。所有这些1,4,7-三氮杂环壬烷基螯合剂均比DFO和DTPA表现出更强的抗增殖活性。其中,以对-NO 2 -PhPr-NE3TA和对-NH 2为代表的具有苯丙基侧链的螯合剂。-PhPr-NE3TA对HepG2细胞显示出最高的抗增殖活性。因此,这些化合物作为潜在的抗癌疗法中的铁耗竭剂,是进行高级研究的诱人候选物,并且可以与靶向部分进一步结合,以用于靶向铁耗竭疗法的未来发展。